Natera (NASDAQ:NTRA) CFO Sells 782 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 782 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $260.49, for a total value of $203,703.18. Following the completion of the sale, the chief financial officer owned 56,714 shares in the company, valued at approximately $14,773,429.86. This represents a 1.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The shares were sold at an average price of $249.38, for a total transaction of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total transaction of $614,329.24.
• On Monday, May 4th, Michael Burkes Brophy sold 482 shares of Natera stock. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18.
• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The shares were sold at an average price of $206.16, for a total transaction of $64,528.08.

Natera Trading Up 0.6%

Shares of Natera stock traded up $1.60 during trading hours on Wednesday, reaching $253.82. The stock had a trading volume of 925,147 shares, compared to its average volume of 1,091,572. The stock’s 50 day moving average is $244.16 and its 200 day moving average is $221.65. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04. The firm has a market capitalization of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently made changes to their positions in NTRA. Horizon Investments LLC grew its holdings in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC lifted its stake in shares of Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after buying an additional 45 shares in the last quarter. Savvy Advisors Inc. boosted its position in Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the last quarter. Parallel Advisors LLC boosted its position in Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after acquiring an additional 47 shares during the last quarter. Finally, First Horizon Corp boosted its position in Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after acquiring an additional 51 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on NTRA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. UBS Group set a $260.00 price target on shares of Natera in a research note on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Robert W. Baird set a $265.00 price objective on shares of Natera in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.